Skip to content
drillr.ai
Sign up

09926.HK

Akeso, Inc.

HKSE · Healthcare · Biotechnology · CN

HKD 90.50
−0.28%
Ask drillr

  • Sep 17, 2026, 05:36 UTC

    Akeso announced that its AK112 (brand name Yidafang) reported significantly positive overall survival results in the registrational Phase III HARMONI-2 trial for first-line treatment of PD-L1-positive NSCLC at WCLC.

    Source:

  • Sep 17, 2026, 05:03 UTC

    Akeso announced that its independently developed dual-antibody ADC drug AK158D1 (EGFR/Trop2) received approval from the Center for Drug Evaluation of the National Medical Products Administration to conduct a Phase I clinical study for the treatment of advanced malignant solid tumors.

    Source:

  • Sep 17, 2026, 03:53 UTC

    Akeso's AK112 (ivonescimab) presented Phase III HARMONI-2 trial data in first-line PD-L1-positive non-small cell lung cancer versus Keytruda at WCLC 2026.

    Source:

  • Sep 16, 2026, 04:12 UTC

    Hong Kong stocks closed the morning session higher, with the Hang Seng Index up 30 points at 24,697 and the Hang Seng Tech Index up 37 points at 4,328, while Hua Hong Semiconductor rose over 7% and Haiqing Zhiyuan hit a record high.

    Source:

  • Sep 14, 2026, 08:12 UTC

    Hong Kong stocks closed higher on September 14, 2026, with the Hang Seng Index up 111 points or 0.5% at 24,917, while the Hang Seng Tech Index slipped 2 points or 0.1% to 4,317 and the China Enterprises Index rose 38 points or 0.5% to 8,284 on turnover of HK$192.625 billion.

    Source:

  • Sep 14, 2026, 04:53 UTC

    Akeso Inc. released updated overall survival data from the HARMONi-2 trial of ivonescimab, showing a median OS of 30.8 months versus 22.6 months for pembrolizumab with a hazard ratio of 0.73.

    Source:

  • Sep 14, 2026, 04:12 UTC

    Hong Kong stocks closed the morning session higher on September 14, 2026, with the Hang Seng Index up 87 points at 24,893 and the Hang Seng Tech Index up 7 points at 4,327.

    Source:

  • Sep 14, 2026, 03:57 UTC

    Akeso Inc. shares opened 4.49% higher and rose as much as 4.82% to HK$96.55 on September 14, 2026, with 11.8951 million shares traded worth HK$1.109 billion.

    Source:

  • Sep 11, 2026, 08:12 UTC

    Hong Kong's Hang Seng Index closed down 148 points, or 0.6%, at 24,805, while the Hang Seng Tech Index fell 9 points, or 0.2%, to 4,320, with market turnover of HK$228.431 billion.

    Source:

  • Sep 4, 2026, 05:33 UTC

    CStone Pharmaceuticals reported first-half 2026 results with revenue of 1.806 billion yuan, up 27.9% year-on-year, and a net loss attributable to shareholders of 424 million yuan.

    Source:

  • Sep 4, 2026, 01:43 UTC

    Akeso announced that its self-developed bispecific antibody ivonescimab achieved statistically significant and clinically beneficial positive results in an interim overall survival analysis of the Phase III HARMONi-2 study for first-line treatment of PD-L1-positive non-small cell lung cancer.

    Source:

  • Sep 2, 2026, 21:41 UTC

    Akeso Inc. announced positive overall survival results from the Phase III HARMONi-2 study, showing ivonescimab monotherapy significantly improved OS versus pembrolizumab in PD-L1-positive advanced NSCLC.

    Source:

  • Aug 27, 2026, 14:02 UTC

    Akeso Inc. reported its first-half 2026 financial results, with revenue of RMB 1.806 billion, up 27.92% year-on-year, and a net loss of RMB 447 million, narrowing from a loss of RMB 588 million in the same period of 2025.

    Source:

  • Jul 24, 2026, 08:40 UTC

    Libo Medicine (09637) announced that its joint representatives have fully exercised the 15% over-allotment option, involving 8.5133 million H-shares at an issue price of HKD 22.6 per share, raising net additional proceeds of HKD 184.7 million to cover over-allotments in the international offering.

    Source:

  • Jul 20, 2026, 05:49 UTC

    Akeso announced the dosing of the first patient in a Phase II clinical study of its TROP2/Nectin-4 bispecific ADC AK146D1 in combination with ivonescimab for advanced NSCLC.

    Source:

  • Jun 15, 2026, 06:52 UTC

    Akeso enrolled the first patient in a Phase Ib/II clinical study of its next-generation HER3 ADC AK138D1, alone or with ivonescimab, for advanced breast cancer.

    Source:

  • Jun 1, 2026, 07:02 UTC

    Akeso is investing significantly to expand manufacturing of its lung cancer drug.

    Source:

  • May 31, 2026, 12:00 UTC

    Akeso and Summit Therapeutics presented positive Phase 3 trial results for their experimental lung cancer drug ivonescimab at the American Society of Clinical Oncology annual meeting.

    Source: